We report an emergency paired donor interchange living donor liver transplant performed on January 13, 2009. The 4 operations (2 liver transplants) were performed simultaneously. The aim was to avoid 2 ABO-incompatible liver transplants. One recipient in acute liver failure underwent transplantation
Present status of ABO-incompatible living donor liver transplantation in Japan
β Scribed by Hiroto Egawa; Satoshi Teramukai; Hironori Haga; Minoru Tanabe; Masanori Fukushima; Motohide Shimazu
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 306 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) has been performed in Japan to overcome the organ shortage. Reported herein are the results of this approach through March 2006 in the National Registry of the Japan Study Group for ABO-incompatible transplantation. The questionnaires consisted of patient characteristics, operative data, and strategies for preventing antibody-mediated rejection (AMR). Data of 291 patients (follow-up period, 8 months-15 years; mean, 35 months) from 28 institutions were collected. Age was younger than 1 year in 68 patients, 1 to 7 years in 60 patients, 8 to15 years in 27 patients, and 16 years or older in 136 patients. The strategy for the blood-type barrier was heterogeneous in terms of recipient age, transplant center, and era. Local infusion and rituximab prophylaxis were applied in 2000 and 2003, respectively. The 5-year patient survival rate was 85% in infants and 52% in adults. The major causes of death were infection and antibody-mediated rejection (AMR). Multivariate analysis showed that age group, preoperative condition, antibody titer, and infection significantly affected survival. Age group, antibody titer, and local infusion treatment significantly affected the incidence of AMR. Patient survival rates were significantly higher and the incidence of AMR was significantly lower in adult patients after 2000 (3 year-survival rate, 29%, 56%, and 61%; incidence of AMR, 47%, 27%, and 16%, through May 2000, from June 2000 through October 2003, and from November 2003, respectively). Conclusion: ABO-incompatible LDLT is a standard practice in children, and local infusion and rituximab prophylaxis are promising in adults.
π SIMILAR VOLUMES
ABO incompatibility is the most common cause of donor rejection during the initial screening of adult patients with end-stage liver disease for living donor liver transplantation (LDLT). A paired donor exchange program was initiated to cope with this problem without ABO-incompatible LDLT. We present
Although the effectiveness of rituximab has been reported in ABO blood group (ABO)-incompatible (ABO-I) organ transplantation, the protocol is not yet established. We studied the impact of the timing of rituximab prophylaxis and the humoral immune response of patients undergoing ABO-I living donor l
ABO blood group compatibility has been regarded as an essential prerequisite for successful adult living donor liver transplantation (LDLT). Novel strategies for overcoming the ABO blood group barrier, however, have markedly improved the results of ABO-incompatible (ABOi) LDLT. We describe our strat
## Abstract ## Background: ABOβincompatible (ABOβi) liver transplantation (LT) is a highβrisk procedure due to the potential for antibodyβmediated rejection (AMR) and cellβmediated rejection. The aim of the current report is to illustrate the results of a retrospective comparison study on the use